Patents by Inventor Christine A. White

Christine A. White has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190382474
    Abstract: The present disclosure relates to anti-IL-27 antibodies, and antigen-binding portions thereof. The disclosure also relates to methods for treating or ameliorating one or more symptoms of a disease, such as cancer, by administering the antibodies or antigen-binding portion thereof. The disclosure also relates to methods for detecting IL-27 in, for example, a subject or a sample.
    Type: Application
    Filed: March 22, 2019
    Publication date: December 19, 2019
    Inventors: Jonathan HILL, Scott CHAPPEL, Michael GLADSTONE, Bianka PRINZ, Andrew LAKE, Christine MILLER, Kerry WHITE, Jing HUA, Pamela M. HOLLAND, Matthew RAUSCH, Devapregasan MOODLEY
  • Patent number: 10400043
    Abstract: The present invention concerns methods for the treatment of diffuse large cell lymphoma by administration of an anti-CD20 antibody and chemotherapy. Particular embodiments include the administration of anti-CD20 antibody in combination with chemotherapy comprising CHOP (cyclophosphamide, hydroxydaunorubicin/doxorubicin, vincristine, and prednisone/prednisolone) and/or in combination with a transplantation regimen.
    Type: Grant
    Filed: December 28, 2017
    Date of Patent: September 3, 2019
    Assignee: Biogen, Inc.
    Inventors: Christine A. White, Antonio J. Grillo-Lopez
  • Publication number: 20180118844
    Abstract: The present invention concerns methods for the treatment of diffuse large cell lymphoma by administration of an anti-CD20 antibody and chemotherapy. Particular embodiments include the administration of anti-CD20 antibody in combination with chemotherapy comprising CHOP (cyclophosphamide, hydroxydaunorubicin/doxorubicin, vincristine, and prednisone/prednisolone) and/or in combination with a transplantation regimen.
    Type: Application
    Filed: December 28, 2017
    Publication date: May 3, 2018
    Inventors: Christine A. White, Antonio J. Grillo-Lopez
  • Publication number: 20170037139
    Abstract: The present invention concerns methods for the treatment of diffuse large cell lymphoma by administration of an anti-CD20 antibody and chemotherapy. Particular embodiments include the administration of anti-CD20 antibody in combination with chemotherapy comprising CHOP (cyclophosphamide, hydroxydaunorubicin/doxorubicin, vincristine, and prednisone/prednisolone) and/or in combination with a transplantation regimen.
    Type: Application
    Filed: October 25, 2016
    Publication date: February 9, 2017
    Inventors: Christine A. White, Antonio J. Grillo-Lopez
  • Patent number: 9504744
    Abstract: The present invention concerns methods for the treatment of diffuse large cell lymphoma by administration of an anti-CD20 antibody and chemotherapy. Particular embodiments include the administration of anti-CD20 antibody in combination with chemotherapy comprising CHOP (cyclophosphamide, hydroxydaunorubicin/doxorubicin, vincristine, and prednisone/prednisolone) and/or in combination with a transplantation regimen.
    Type: Grant
    Filed: June 20, 2014
    Date of Patent: November 29, 2016
    Assignee: Biogen Inc.
    Inventors: Christine A. White, Antonio J. Grillo-Lopez
  • Publication number: 20140302018
    Abstract: The present invention concerns methods for the treatment of diffuse large cell lymphoma by administration of an anti-CD20 antibody and chemotherapy. Particular embodiments include the administration of anti-CD20 antibody in combination with chemotherapy comprising CHOP (cyclophosphamide, hydroxydaunorubicin/doxorubicin, vincristine, and prednisone/prednisolone) and/or in combination with a transplantation regimen.
    Type: Application
    Filed: June 20, 2014
    Publication date: October 9, 2014
    Inventors: Christine A. White, Antonio J. Grillo-Lopez
  • Patent number: 8821873
    Abstract: The present invention concerns methods for the treatment of diffuse large cell lymphoma by administration of an anti-CD20 antibody and chemotherapy. Particular embodiments include the administration of anti-CD20 antibody in combination with chemotherapy comprising CHOP (cyclophosphamide, hydroxydaunorubicin/doxorubicin, vincristine, and prednisone/prednisolone) and/or in combination with a transplantation regimen.
    Type: Grant
    Filed: October 3, 2013
    Date of Patent: September 2, 2014
    Assignee: Biogen Idec Inc.
    Inventors: Christine A. White, Antonio J. Grillo-Lopez
  • Publication number: 20140030263
    Abstract: The present invention concerns methods for the treatment of diffuse large cell lymphoma by administration of an anti-CD20 antibody and chemotherapy. Particular embodiments include the administration of anti-CD20 antibody in combination with chemotherapy comprising CHOP (cyclophosphamide, hydroxydaunorubicin/doxorubicin, vincristine, and prednisone/prednisolone) and/or in combination with a transplantation regimen.
    Type: Application
    Filed: October 3, 2013
    Publication date: January 30, 2014
    Applicant: Biogen Idec Inc.
    Inventors: Christine A. White, Antonio J. Grillo-Lopez
  • Patent number: 8557244
    Abstract: This invention concerns methods for the treatment of intermediate and high-grade non-Hodgkins lymphomas, comprising the administration of anti-CD20 monoclonal antibodies and fragments thereof. Particular embodiments include the administration of chimeric anti-CD20 antibody, either alone or in combination with radiolabeled antibodies or chemotherapy. The invention is particularly useful for lymphomas characterized by a high number of circulating B cells, possibly bone marrow involvement, bulky disease, or the involvement of extralymphatic organs or sites.
    Type: Grant
    Filed: July 28, 2000
    Date of Patent: October 15, 2013
    Assignee: Biogen Idec Inc.
    Inventors: Christine White, Antonio Grillo-Lopez
  • Patent number: 8206711
    Abstract: Chronic Lymphocytic Leukemia (CLL) may be treated with antibodies directed against the CD20 antigen.
    Type: Grant
    Filed: December 2, 2009
    Date of Patent: June 26, 2012
    Assignees: Biogen Idec Inc., Genentech, Inc.
    Inventors: Christine A. White, Antonio J. Grillo-Lopez, John G. Curd, Susan Desmond-Hellmann
  • Publication number: 20110150193
    Abstract: A method includes developing a call profile for a call that has been identified for intercept treatment, the call comprising a call from a caller to a disconnected listing. The developing comprises accessing one or more listing characteristics for the disconnected listing independently of the caller. The method further includes selecting a targeted advertisement for the caller based at least in part on the call profile. Additionally, the method includes reporting to the caller regarding the disconnected listing, the reporting comprising presenting the targeted advertisement to the caller.
    Type: Application
    Filed: December 15, 2010
    Publication date: June 23, 2011
    Inventors: Nelson Cain, Rick Kodweis, Christine Whites
  • Publication number: 20100080769
    Abstract: Chronic Lymphocytic Leukemia (CLL) may be treated with antibodies directed against the CD20 antigen.
    Type: Application
    Filed: December 2, 2009
    Publication date: April 1, 2010
    Applicants: BIOGEN IDEC INC., GENENTECH, INC.
    Inventors: Antonio J. Grillo-Lopez, Christine A. White, John G. Curd, Susan Desmond-Hellmann
  • Patent number: 7682612
    Abstract: Chronic Lymphocytic Leukemia (CLL) may be treated with antibodies directed against the CD20 antigen.
    Type: Grant
    Filed: November 9, 1999
    Date of Patent: March 23, 2010
    Assignees: Biogen Idec Inc., Genentech, Inc.
    Inventors: Christine A. White, Antonio J. Grillo-López, John G. Curd, Susan Desmond-Hellmann
  • Publication number: 20070148714
    Abstract: New clinical parameters are reported which may serve as predictors of the hematological toxicity associated with therapeutic radiolabeled antibodies, particularly those antibodies which target lymphoma cells which have a tendency to localize to the bone marrow.
    Type: Application
    Filed: February 27, 2007
    Publication date: June 28, 2007
    Inventors: William Raestetter, Christine White
  • Patent number: 7195750
    Abstract: New clinical parameters are reported which may serve as predictors of the hematological toxicity associated with therapeutic radiolabeled antibodies, particularly those antibodies which target lymphoma cells which have a tendency to localize to the bone marrow.
    Type: Grant
    Filed: July 16, 2002
    Date of Patent: March 27, 2007
    Assignee: Biogen IDEC Inc.
    Inventors: William Raestetter, Christine A. White
  • Publication number: 20050112060
    Abstract: Treatment of B-cell associated diseases including autoimmune and B-cell malignancies such as leukemias, lymphomas, using the combination of an anti-CD20 antibody, preferably RITUXAN® and a radiolabeled anti-CD22 antibody, preferably an 90Y labeled humanized anti-CD22 antibody, is described. These therapeutic regimens provide for enhanced depletion of B cells, and therefore reduce the risk in B cell malignancy treatment of relapse associated with RITUXAN® and, moreover, provide for prolonged immunosuppression of B-cell immune responses, especially in the context of autoimmune diseases and transplant.
    Type: Application
    Filed: November 10, 2003
    Publication date: May 26, 2005
    Inventor: Christine White
  • Patent number: 6846476
    Abstract: Treatment of B-cell associated diseases including autoimmune and B-cell malignancies such as leukemias, lymphomas, using the combination of an anti-CD20 antibody, preferably RITUXAN® and a radiolabeled anti-CD22 antibody, preferably an 90Y labeled humanized anti-CD22 antibody, is described. These therapeutic regimens provide for enhanced depletion of B cells, and therefore reduce the risk in B cell malignancy treatment of relapse associated with RITUXAN® and, moreover, provide for prolonged immunosuppression of B-cell immune responses, especially in the context of autoimmune diseases and transplant.
    Type: Grant
    Filed: June 20, 2001
    Date of Patent: January 25, 2005
    Assignee: IDEC Pharmaceuticals Corporation
    Inventor: Christine White
  • Publication number: 20030211038
    Abstract: New clinical parameters are reported which may serve as predictors of the hematological toxicity associated with therapeutic radiolabeled antibodies, particularly those antibodies which target lymphoma cells which have a tendency to localize to the bone marrow.
    Type: Application
    Filed: July 16, 2002
    Publication date: November 13, 2003
    Applicant: IDEC PHARMACEUTICALS CORPORATION
    Inventors: William H. Rastetter, Christine A. White
  • Patent number: 6451284
    Abstract: New clinical parameters are reported which may serve as predictors of the hematological toxicity associated with therapeutic radiolabeled antibodies, particularly those antibodies which target lymphoma cells which have a tendency to localize to the bone marrow.
    Type: Grant
    Filed: July 26, 2000
    Date of Patent: September 17, 2002
    Assignee: IDEC Pharmaceuticals Corporation
    Inventors: William Raestetter, Christine A. White
  • Patent number: 6405139
    Abstract: A system for monitoring machine data which avoids the need for the cumbersome placement of junction boxes adjacent machines that heretofore had required installing the junction boxes on walls, studs, or stanchions. Instead, a rigid conduit having conductors therein communicate with an integrated sealed instrument package that allows the conductors' communication between an asset such as a machine to be monitored via transducers to a signal processor at a remote location. A multiplicity of assets can be monitored through this arrangement by providing signal differentiation for the various machines.
    Type: Grant
    Filed: September 15, 1998
    Date of Patent: June 11, 2002
    Assignee: Bently Nevada Corporation
    Inventors: Walter Kicinski, Christine White